Evidence map›Paper›PMID 39753084›Full record

ArticleBiomaterials2025

Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder.

Hadi Sudarjat, Chaolong Qin, Diane Ingabire, Aji Alex Moothedathu Raynold, Rudra Pangeni, Adam Pearcy, Tuo Meng, Long Zhao, Michelle Arriaga, Woon N Chow and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hadi SudarjatDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Chaolong QinDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Diane IngabireDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Aji Alex Moothedathu RaynoldDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Rudra PangeniDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Adam PearcyDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Tuo MengDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Long ZhaoDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Michelle ArriagaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Woon N ChowDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Jennifer L PuetzerDepartment of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Xiuling LuDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, 06269, USA.
F Gerard MoellerDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Matthew S HalquistDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Charles O'KeeffeDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Qingguo XuDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, 23298, USA; Center for Pharmaceutical Engineering, Center for Drug Discovery, Department of Pediatrics, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA. Electronic address: qxu@vcu.edu.

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · VIRGINIA COMMONWEALTH UNIVERSITY · 1985 to 2025
$4.0M
Novel Therapeutics for Treating Opioid Use DisorderF31DA060668 · VIRGINIA COMMONWEALTH UNIVERSITY · 2025 to 2025
$49k
NIDA NIH HHS F31 DA060668NIDA NIH HHS P30 DA033934NIDA NIH HHS T32 DA007027NIDA NIH HHS UG3 DA048768
6 · The paper itself

Abstract

The opioid crisis has claimed approximately one million lives in the United States since 1999, underscoring a significant public health concern. This surge in opioid use disorder (OUD) fatalities necessitates improved therapeutic options. Current OUD therapies often require daily clinical visits, leading to poor patient compliance and high costs to the health systems. Levo-alpha-acetylmethadol (LAAM) is a long-lasting OUD drug, and the thrice-weekly oral LAAM solution can offer better patient compliance compared to the traditional daily methadone therapies. However, LAAM is FDA-approved but withdrawn from the market. As part of the NIH HEAL Initiative, we aim to reintroduce LAAM back to the market to improve OUD therapeutic options by developing a novel Janus LAAM-loaded fibrous buccal film (LFBF) formulation made of a drug-containing electrospun fibrous layer and a backing layer. The buccal administration of LFBF exhibited superior transmucosal delivery of LAAM to systemic circulation with a nearly 4-fold higher drug bioavailability than the conventional oral LAAM solution in rabbits. Furthermore, upon buccal administration in an opioid-dependent rat model, the LFBF significantly decreased fentanyl choice in the fentanyl-dependent rats, while the conventional oral LAAM solution did not at the same dose. Both the buccal film and oral solution of LAAM reduced somatic withdrawal signs in the experimental animals. These findings highlight the buccal delivery of LAAM using electrospun fibers as a promising strategy with improved drug bioavailability. Furthermore, it sheds light on future clinical applications aiming for enhanced treatment outcomes in the battle against the current opioid crisis.

Indexed as

Analgesics, OpioidOpioid-Related DisordersAdministration, BuccalAnimalsMaleMouth MucosaRabbitsRatsRats, Sprague-DawleyAnalgesics, OpioidBuccal deliveryDrug abuseElectrospinningMuco-adhesionPharmacokineticsTransmucosal drug delivery

Identifiers

PMID39753084
PMCPMC11788036

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.